icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
Impact of Anemia and Ribavirin Dose Reduction on SVR to a Telaprevir-based Regimen in Patients with HCV Genotype 1 and Prior Peginterferon/Ribavirin Treatment Failure in the Phase III REALIZE Study
 
 
  Reported by Jules Levin
AASLD Nov 5-8 2011 SF
 
Stuart Roberts,1 Pietro Andreone,2 Stanislas Pol,3 Zobair Younossi,4 Moises Diago,5 Eric J Lawitz,6 Roberto Focaccia,7 Graham R Foster,8 Andrzej Horban,9 Isabelle Lonjon-Domanec,10 Ralph DeMasi,11 Rudolf van Heeswijk,12 Gaston Picchio,11 James Witek,11 Stefan Zeuzem13
1Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia; 2UniversitÓ di Bologna, Bologna, Italy; 3Universite Paris Descartes, INSERM Unite 1016, and Assistance Publique-Hopitaux de Paris, Cochin Hospital, Paris, France; 4Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 5Hospital General de Valencia, Valencia, Spain; 6Alamo Medical Research, San Antonio, TX, USA; 7Emilio Ribas Infectious Diseases Institute, Sao Paulo, Brazil; 8Queen Marys University of London, Institute of Cell and Molecular Science, London, UK; 9Medical University of Warsaw, Wolska, Warsaw, Poland; 10Janssen Pharmaceuticals, Paris, France; 11Tibotec Inc., Titusville, NJ, USA; 12Tibotec BVBA, Beerse, Belgium; 13Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif